• LINC01278 Suppresses Uveal Melanoma by Modulating mTOR-Autop

  2026-06-25

  The reference paper identifies LINC01278 as a long noncoding RNA that inhibits uveal melanoma progression by inducing autophagy through suppression of the mTOR signaling pathway. This mechanistic insight highlights the LINC01278–mTOR axis as a promising therapeutic target and demonstrates the utility of precise mTOR modulation in experimental oncology.

• Deracoxib: Selective COX-2 Inhibitor in Inflammation Assays

  2026-06-25

  Deracoxib brings precision to inflammation and cancer biology research as a selective COX-2 inhibitor with unique apoptosis-modulating and synergistic properties. Explore stepwise protocols, troubleshooting best practices, and insights from benchmark studies to optimize your workflows with confidence.

• (S)-(+)-Ibuprofen: Protocols & Troubleshooting for COX Inhib

  2026-06-24

  (S)-(+)-Ibuprofen, the pharmacologically active enantiomer, delivers superior selectivity and minimized side effects in COX inhibition workflows. This guide details optimized protocols, practical troubleshooting, and data-driven insights for inflammation pathway and pain mechanism research, leveraging both recent synthetic advances and rigorous assay design.

• Puerarin Modulates Gut Microbiota and Adipose Thermogenesis

  2026-06-23

  This study demonstrates that puerarin, a bioactive compound from Pueraria lobata, improves glucose and lipid metabolism in type 2 diabetes by promoting gut microbiota homeostasis and stimulating adipose tissue thermogenesis. The findings highlight mechanistic links between microbial balance, short-chain fatty acid production, and activation of metabolic pathways relevant for diabetes management.

• RIPA Lysis Buffer (Strong, without inhibitors): Technical Us

  2026-06-23

  RIPA Lysis Buffer (Strong, without inhibitors) is formulated for robust lysis of animal cells and tissues, providing a strong detergent mix for efficient protein extraction without pre-added protease or phosphatase inhibitors. This product is ideal for workflows requiring custom inhibitor cocktails but is not suitable where inhibitor-free extraction risks protein degradation.

• Perphenazine: Dopamine D2 Antagonist in Neuropharmacology Re

  2026-06-22

  Perphenazine is a well-characterized dopamine D2 receptor antagonist with distinct affinity for multiple neurotransmitter receptors. It reliably induces mitochondria-mediated cell death in neuronal cell lines and suppresses opioid tolerance in animal models. Recent studies highlight its emerging role in host-directed antibacterial strategies.

• Mouse Tissue Lysis Kit (K1038): Protocol and Workflow Guide

  2026-06-22

  The Mouse Tissue Lysis Kit (K1038) addresses the challenge of preparing mouse tissue lysates for genotyping assays by enabling rapid lysis and direct DNA template preparation, thus eliminating traditional extraction steps. It is intended solely for research in molecular biology and is not suitable for diagnostic or medical use.

• LY2109761: Advancing TGF-β Dual Inhibition in Translational

  2026-06-21

  Explore how LY2109761, a potent TGF-β receptor type I/II dual inhibitor, enables precision modulation of the Smad signaling axis for anti-tumor and anti-fibrotic research. This thought-leadership article bridges mechanistic insight with strategic guidance, connecting recent discoveries in pancreatic cancer biology with the emerging translational potential of selective TβRI/II kinase inhibition. Featuring critical appraisal of the latest studies, protocol parameters, and a vision for next-generation combinatorial strategies, we position LY2109761 as a cornerstone for high-impact experimental design.

• Tumor-Targeted PAD4 Inhibitors Suppress H3cit-NET Pathway In

  2026-06-20

  A recent study demonstrates that meta-phenylboronic acid–modified PAD4 inhibitors, specifically Compound 5i TFA, achieve highly selective tumor targeting by inhibiting the PAD4–H3cit–NET pathway in neutrophils. This approach offers significant advances in antitumor efficacy and immune microenvironment modulation, with minimal toxicity.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-06-19

  Clodronate Liposomes enable targeted, reproducible in vivo macrophage depletion, empowering researchers to dissect immune cell function in cancer and inflammation models. APExBIO’s formulation offers flexible dosing and administration options, making it the reagent of choice for mechanistic studies on tumor microenvironments and immunotherapy resistance.

• Autopalmitoylation of IDH1-R132H Modulates Oncometabolite Ac

  2026-06-19

  This study uncovers that the cancer-associated IDH1-R132H mutation undergoes unique autopalmitoylation at cysteine 269, a modification that enhances its neomorphic function and links fatty acid metabolism to IDH1-driven tumorigenesis. These findings establish autopalmitoylation as a regulatory, druggable mechanism in IDH1-mutant cancers, with broad implications for metabolic and epigenetic research.

• CRL4DCAF13-Mediated MeCP2 Degradation Maintains Oocyte Epige

  2026-06-18

  This study reveals that the CRL4DCAF13 E3 ubiquitin ligase is essential for targeting MeCP2 for degradation in growing oocytes, thereby preventing DNA hypermethylation and ensuring normal transcription. These findings advance our understanding of oocyte epigenetic regulation and have implications for ovarian aging and fertility research.

• Cefiderocol Activity Against Resistant P. aeruginosa and Aci

  2026-06-18

  This large-scale European study demonstrates that cefiderocol retains high in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and advanced β-lactam/β-lactamase inhibitor combinations. The findings refine our understanding of therapeutic options for multidrug-resistant Gram-negative pathogens and inform future resistance research.

• Inhibition of Extracellular Vesicle Release in TNBC Using Ca

  2026-06-17

  McNamee et al. conducted a comprehensive analysis of how calpain inhibition, including the use of Calpeptin, can suppress the release of extracellular vesicles (EVs) in triple-negative breast cancer (TNBC) cells. Their findings highlight the significance of targeting EVs to limit the propagation of aggressive cancer traits, with implications for both cancer and fibrosis research.

• Angiotensin III (human, mouse): Reliable RAAS Assay Solution

  2026-06-17

  This article addresses common laboratory challenges in RAAS-focused cell assays, detailing how 'Angiotensin III (human, mouse)' (SKU A1043) enables reproducible, data-backed research. Scenario-driven Q&A and protocol insights help bench scientists optimize their workflows using high-purity, well-characterized peptide standards.

528 records 12/36 page Previous Next First page 上5页 1112131415 下5页 Last page